Article Details
Retrieved on: 2025-09-27 16:28:53
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a ...
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here